Enliven Therapeutics, Inc.
General ticker "ELVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.0B (TTM average)
Enliven Therapeutics, Inc. follows the US Stock Market performance with the rate: 27.9%.
Estimated limits based on current volatility of 5.3%: low 18.67$, high 20.78$
Factors to consider:
- Total employees count: 46 as of 2023
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [12.82$, 35.64$]
- 2025-12-31 to 2026-12-31 estimated range: [9.41$, 27.45$]
Financial Metrics affecting the ELVN estimates:
- Negative: with PPE of -12.0 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.85 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: -4.48 < Investing cash flow per share per price, % of -3.37
- Positive: Shareholder equity ratio, % of 95.11 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ELVN quotes
Long-term ELVN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $38.79MM | $83.53MM | $104.55MM |
| Operating Income | $-38.79MM | $-83.53MM | $-104.55MM |
| Non-Operating Income | $1.13MM | $11.95MM | $15.76MM |
| R&D Expense | $31.02MM | $64.57MM | $80.78MM |
| Income(Loss) | $-37.66MM | $-71.58MM | $-88.79MM |
| Taxes | $0.00MM | $0.00MM | $0.23MM |
| Profit(Loss)* | $-37.66MM | $-71.58MM | $-89.02MM |
| Stockholders Equity | $-76.83MM | $245.91MM | $309.85MM |
| Assets | $83.30MM | $271.87MM | $325.76MM |
| Operating Cash Flow | $-32.08MM | $-61.27MM | $-73.19MM |
| Capital expenditure | $0.61MM | $0.15MM | $0.04MM |
| Investing Cash Flow | $-0.61MM | $-148.41MM | $-36.00MM |
| Financing Cash Flow | $-1.80MM | $234.29MM | $133.16MM |
| Earnings Per Share** | $-6.03 | $-2.01 | $-1.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.